Home / Research library / Liraglutide
Liraglutide: molecular data, studies & sources
Liraglutide is catalogued here as a research compound. This profile brings together the molecular source record, selected indexed publications and available supplier comparisons. Evidence for a named substance does not authenticate a commercial product.
Compiled by PeptideTech Editors · Sources checked · Selected bibliography, not a systematic review
Molecular formula, weight & structure
- Molecular formula (MF)
- C172H265N43O51
- Molecular weight (MW)
- 3751 g/mol
- PubChem compound ID
- 16134956
- Record title
- Liraglutide
Values describe the selected PubChem molecular entity. Counterions, salt forms, hydration and sequence changes can alter the supplied material. Confirm the exact identity against the supplier specification.
Source: PubChem CID 16134956 · retrieved 2026-09-21
Chemical identifiers and source data
- IUPAC name
- (2S)-5-[[(5S)-5-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]propanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-5-oxopentanoyl]amino]propanoyl]amino]propanoyl]amino]-6-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-carbamimidamido-1-[[2-[[(2S)-5-carbamimidamido-1-(carboxymethylamino)-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-6-oxohexyl]amino]-2-(hexadecanoylamino)-5-oxopentanoic acid
- InChIKey
- YSDQQAXHVYUZIW-QCIJIYAXSA-N
- SMILES
- CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCCC[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CC6=CN=CN6)N)C(=O)O
Identifiers
- PubChem CID
- 16134956
- CAS Registry Number
- 204656-20-2via ChemIDplus, EPA DSSTox, FDA GSRS
- FDA UNII
- 839I73S42A
- ChEMBL ID
- CHEMBL4084119
- InChIKey
- YSDQQAXHVYUZIW-QCIJIYAXSA-N
Other names and development codes: NN-2211 · NN-9924 · NNC 90-1170
CAS numbers are published only from ChemIDplus, EPA DSSTox or the FDA Global Substance Registration System; UNII codes are confirmed in FDA GSRS by structure, sequence or exact name. Checked 2026-10-07.
Calculated molecular descriptors
| Monoisotopic (exact) mass | 3748.9465 Da |
|---|---|
| Heavy atoms | 266 |
| Hydrogen-bond donors | 54 |
| Hydrogen-bond acceptors | 49 |
| Rotatable bonds | 130 |
| Topological polar surface area | 1513.8 Ų |
| Calculated logP (Crippen) | -10.16 |
| Rings | 6 |
| Stereocenters | 31 |
| Formal charge | 0 |
Computed with RDKit from the published SMILES (Crippen logP, topological polar surface area). Calculated descriptors are not measured properties of a supplied batch.
US regulatory status & drug development
Liraglutide is the active ingredient of FDA-approved medicines that Drugs@FDA lists as marketed prescription products (checked October 7, 2026): VICTOZA (NDA 022341, approved January 25, 2010) and SAXENDA (NDA 206321, approved December 23, 2014). Drugs@FDA also lists 11 approved generic (ANDA) applications. Research-labelled Liraglutide listings are not VICTOZA or SAXENDA and are not FDA-approved drugs.
| Medicine | Application | Sponsor | First approval | Marketing status |
|---|---|---|---|---|
| VICTOZAliraglutide | NDA 022341DailyMed label: Liraglutide · 2026-01-30DailyMed label: Victoza · 2025-10-14 | NOVO NORDISK INC | Prescription | |
| SAXENDAliraglutide | NDA 206321DailyMed label: Saxenda · 2026-02-25DailyMed label: Saxenda · 2024-01-26 | NOVO | Prescription |
Drugs@FDA also lists 11 approved generic (ANDA) applications for this active ingredient.
An FDA approval covers a defined medicine, formulation and labelled use. It does not extend to research-labelled material sold under the same compound name. Identity basis: Same active ingredient name (liraglutide).
Source: Drugs@FDA via openFDA (application records; DailyMed label set IDs) · checked . openFDA data are not intended for clinical decisions.
Drug development record (ChEMBL)
Harmonized drug-development record from ChEMBL. The highest clinical stage is the furthest stage reached, as recorded by ChEMBL; it can lag regulatory approvals, and it is not an approval of a research-supplier product.
- ChEMBL ID
- CHEMBL4084119
- Modality
- Protein / peptide
- Highest clinical stage
- Approved in at least one jurisdiction (ChEMBL phase 4)
- Record name
- LIRAGLUTIDE
Mechanism of action
- Glucagon-like peptide 1 receptor agonist · target: Glucagon-like peptide 1 receptor (GLP1R)
Synonyms, codes and trade names
- Trade and brand names (Drugs@FDA)
- LIRAGLUTIDE · SAXENDA · VICTOZA
- Synonyms and development codes
- Liraglutide · NN-2211 · NN-9924 · NN2211 · NN9924 · NNC 90-1170 · NNC-90-1170
Identity check: Identical standard InChIKey to the PubChem record. Source: ChEMBL CHEMBL4084119 (EMBL-EBI, CC BY-SA 3.0) · retrieved 2026-10-07
Registered clinical trials
Studies registered on ClinicalTrials.gov that list Liraglutide as an intervention. Studies that only measure the molecule as a biomarker, or use it only as a comparator or background arm for another drug, are excluded. A registration describes a planned or completed protocol; it does not report a result. Active studies are listed first.
33 registered studies matched, 5 currently active or recruiting, 3 with results posted on ClinicalTrials.gov.
- By highest phase
- Phase 4 · 10Phase 3 · 8Phase 2 · 2Phase 1 · 3Not applicable · 10
- By registry status
- Completed · 17Unknown · 8Not Yet Recruiting · 2Recruiting · 2Withdrawn · 2Active Not Recruiting · 1Terminated · 1
| Study | Phase · status | Conditions | Sponsor · size |
|---|---|---|---|
| RWS of of Liraglutide Alone and in Combination With Orlistat for Weight Loss in Overweight/Obese Patients.NCT07301437 · start 2026-05-01 · primary completion 2027-08-31 | Phase 4Not Yet Recruiting | Overweight and Obese Adults | The Fourth Affiliated Hospital of Zhejiang University School of Medicine120 participants |
| Preoperative Use of Liraglutide Additionally to Common Dietological Measures as Opposed to Dietological Measures AloneNCT06865365 · start 2025-05-01 · primary completion 2027-02-01 | Phase 4Not Yet Recruiting | Obesity, Adolescent | Medical University of Vienna72 participants |
| Safety, Tolerability and Preliminary Efficacy of Sublingual Liraglutide in Patients With Type 2 Diabetes MellitusNCT05268237 · start 2023-04-25 · primary completion 2025-12 | Phase 1 / Phase 2Recruiting | Diabete Type 2 | Biolingus15 participants |
| Liraglutide-bolus vs Glargine-bolus Therapy in Overweight/Obese Type 2 Diabetes Patients (LiraGooD)NCT03087032 · start 2019-01-10 · primary completion 2025-01-15 | Phase 4Recruiting | Type 2 Diabetes Patients · Overweight and Obesity · Hyperglycaemia (Diabetic) | The First Affiliated Hospital of Xiamen University164 participants |
| Saxenda: Underlying Mechanisms and Clinical OutcomesNCT02944500 · start 2016-11 · primary completion 2027-06 | Phase 4Active Not Recruiting | Obesity | Beth Israel Deaconess Medical Center28 participants |
| Effect of Liraglutide in Obese Women With Polycystic Ovary SyndromeNCT05965908 · start 2024-08-01 · primary completion 2025-11-30 | Phase 3Completed | Polycystic Ovary | Beni-Suef University183 participants |
| A Trial Investigating the Efficacy and Safety of Insulin Degludec/Liraglutide Injection in Subjects With Type 2 DiabetesNCT06559722 · start 2024-08 · primary completion 2025-10 | Phase 3Unknown | Type 2 Diabetes | Tonghua Dongbao Pharmaceutical Co.,Ltd510 participants |
| LIROH - Liraglutide for Obesity in HIVNCT06438146 · start 2024-05-02 · primary completion 2025-05 | Phase 4Unknown | Obesity · HIV Infections | Brigham and Women's Hospital40 participants |
| Phase 1 Study Assessing the Pharmacokinetics of NEX-22A in Subjects With T2DNCT06439056 · start 2024-05-27 · primary completion 2025-07-18 | Phase 1Completed | Type 2 Diabetes | Nanexa AB12 participants |
| Pharmacological Treatment - An Overview of Its Role in Managing Childhood ObesityNCT07304141 · start 2023-12-20 · primary completion 2025-12-12 | Not applicableCompleted | Obesity (Disorder) · Child Obesity | Göteborg University128 participants |
Show 23 more registered studies
| Study | Phase · status | Conditions | Sponsor · size |
|---|---|---|---|
| Liraglutide and Metformin Combination on Weight Loss, Metabolic - Endocrine Parameters and Pregnancy Rate in Women With PCOS, Obesity and InfertilityNCT05952882 · start 2023-11-01 · primary completion 2025-12-31 | Phase 3Unknown | Polycystic Ovary Syndrome · Obesity · Infertility, Female | Mỹ Đức Hospital188 participants |
| Obesity Treatment to Improve DiabetesNCT05390307 · start 2023-04-01 · primary completion 2024-01-01 | Not applicableCompleted | Type 1 Diabetes | Dasman Diabetes Institute60 participants |
| POSE2.0 With GLP-1 Agonist for Obesity ManagementNCT05705388 · start 2023-01-16 · primary completion 2025-01-03 | Not applicableUnknown | Obesity | Emirates Health Services (EHS)50 participants |
| Risk of Hypoglycemia in the Transition From Inpatient to Outpatient Setting. Comparative Study of Basal-bolus Insulin Versus Basal Insulin Plus GLP-1 AnalogueNCT05767255 · start 2022-12-01 · primary completion 2023-08-30 | Phase 3Unknown | Diabetes Mellitus, Type 2 Treated With Insulin | Hospital Universitario San Ignacio66 participants |
| Liraglutide Effectiveness in Preoperative Weight-loss for Bariatric-metabolic SurgeryNCT06201819 · start 2022-12-18 · primary completion 2023-03-18 | Phase 4Completed | Weight Loss · Bariatric Surgery Candidate · Obesity, Morbid | Hospital Civil Juan I. Menchaca37 participants |
| LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 DiabetesNCT05313529 · start 2022-10-08 · primary completion 2025-12-31 | Not applicableCompleted | Type 2 Diabetes Mellitus · Mild Cognitive Impairment | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School396 participants |
| Efficacy of Liraglutide Therapy in Patients With IPAANCT04763564 · start 2022-03-22 · primary completion 2023-10-16 | Phase 2TerminatedResults posted 2024-07-23Why stopped: Due to an interruption in drug supply, the study was terminated | Pouchitis · Irritable Pouch Syndrome | University of North Carolina, Chapel Hill8 participants |
| A Randomized Phase 1 Study of Liralutide Injection in Healthy Chinese SubjectsNCT05225974 · start 2021-07-16 · primary completion 2021-07-30 | Phase 1Completed | Therapeutic Equivalency | The Affiliated Hospital of Qingdao University32 participants |
| Effects of Degludec/Liraglutide on Time in Range, Inflammation and Endothelial Function vs Insulin Basal Bolus in Diabetic InpatientsNCT05360537 · start 2021-04-01 · primary completion 2021-12-01 | Phase 4Completed | Diabetes Mellitus, Type 2 | University of Palermo100 participants |
| Liraglutide Plus Megestrol Acetate in Endometrial Atypical HyperplasiaNCT04683237 · start 2021-03-20 · primary completion 2025-11-30 | Phase 2 / Phase 3WithdrawnWhy stopped: Based on our latest research results, we will revise the protocol and design a better study. Since no participants are enrolled till now, we withdraw this study. | Atypical Endometrial Hyperplasia · Obese · Fertility Issues | Xiaojun ChenEnrollment not listed |
| Liraglutide and Peripheral Artery DiseaseNCT04881110 · start 2021-02-01 · primary completion 2022-12-31 | Phase 4CompletedResults posted 2025-03-03 | Type 2 Diabetes · Peripheral Arterial Disease | University of Campania Luigi Vanvitelli60 participants |
| Liraglutide for Low-responders After Bariatric SurgeryNCT04643301 · start 2020-12-21 · primary completion 2021-12-31 | Not applicableWithdrawnWhy stopped: Cancellation by sponsor | Obesity · Obesity, Morbid | Zuyderland Medisch CentrumEnrollment not listed |
| A Research Study Looking at Long-term Blood Sugar Control in People With Type 2 Diabetes Being Treated With Xultophy® in a Real-world Setting in ItalyNCT04666987 · start 2020-10-21 · primary completion 2022-12-30 | Not applicableCompleted | Diabetes Mellitus, Type 2 | Novo Nordisk A/S359 participants |
| Clinical Study on the Improvement of Diabetic Neuropathic Pain by LiraglutideNCT04137328 · start 2019-11-30 · primary completion 2022-11-30 | Not applicableUnknown | Diabetic Neuropathic Pain | Fudan University60 participants |
| Research Study to Investigate How Well Semaglutide Works Compared to Liraglutide in People Living With Overweight or ObesityNCT04074161 · start 2019-09-11 · primary completion 2021-03-27 | Phase 3CompletedResults posted 2022-04-27 | Overweight · Obesity | Novo Nordisk A/S338 participants |
| Human Bioequivalence Test of Liraglutide InjectionNCT05029076 · start 2019-05-21 · primary completion 2019-06-01 | Phase 1Completed | Type 2 Diabetes | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.28 participants |
| A Research Study, Looking at How Xultophy® Works in People With Type 2 Diabetes in Local Clinical Practice in United Arab EmiratesNCT03823339 · start 2019-01-29 · primary completion 2020-12-14 | Not applicableCompleted | Diabetes Mellitus, Type 2 | Novo Nordisk A/S300 participants |
| Effect of Liraglutide on Microbiome in ObesityNCT04046822 · start 2019-01-09 · primary completion 2020-01-09 | Phase 4Unknown | Obesity · Weight Loss · Microbiome | Federico II University70 participants |
| Effects of GLP-1 RAs on Weight and Metabolic Indicators in Obese PatientsNCT03671733 · start 2018-09-01 · primary completion 2022-09-01 | Phase 3Unknown | Obesity | Xiangya Hospital of Central South University150 participants |
| The Use of Liraglutide in Brain DeathNCT03672812 · start 2018-09-01 · primary completion 2019-12-10 | Phase 3Completed | Brain Death | Hospital de Clinicas de Porto Alegre50 participants |
| A Regulatory Post-marketing Surveillance (rPMS) Study to Evaluate the Safety and Effectiveness of Saxenda®(Liraglutide 3.0 mg) in Obese Patients and Overweight Patients With Obesity-related Comorbidities in Routine Clinical Practice in Korea.NCT03560336 · start 2018-07-05 · primary completion 2020-12-02 | Not applicableCompleted | Obesity · Overweight | Novo Nordisk A/S758 participants |
| In Market Utilisation of Liraglutide Used for Weight Management in the UK: a Study in the CPRD Primary Care DatabaseNCT03479762 · start 2018-04-20 · primary completion 2022-09-12 | Not applicableCompleted | Obesity · Overweight | Novo Nordisk A/S105 participants |
| Effects of Liraglutide in Chronic Obstructive Pulmonary DiseaseNCT03466021 · start 2018-01-01 · primary completion 2020-05-31 | Phase 4Completed | Pulmonary Disease, Chronic Obstructive | Claus Bogh Juhl40 participants |
Registry check 2026-10-09 · Run this search on ClinicalTrials.gov
Human intervention studies
Selected studies in which participants received Liraglutide, with their indexed or reviewed study type. Check the original article for the formulation, population and controls. Studies that only measured the molecule, or used it as a comparator, are listed separately below and are not counted as intervention studies.
- Human study · PubMed trial index Compound given to participants
Liraglutide for Children 6 to <12 Years of Age with Obesity - A Randomized Trial.
Fox CK, Barrientos-Pérez M, Bomberg EM et al. · The New England journal of medicine · 2025
PMID 39258838 · DOI: 10.1056/NEJMoa2407379
- Human study · PubMed trial index Compound given to participants
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
Pi-Sunyer X, Astrup A, Fujioka K et al. · The New England journal of medicine · 2015
PMID 26132939 · DOI: 10.1056/NEJMoa1411892
- Human study · PubMed trial index Compound given to participants
Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined.
Lundgren JR, Janus C, Jensen SBK et al. · The New England journal of medicine · 2021
PMID 33951361 · DOI: 10.1056/NEJMoa2028198
- Human study · PubMed trial index Compound given to participants
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Marso SP, Daniels GH, Brown-Frandsen K et al. · The New England journal of medicine · 2016
PMID 27295427 · DOI: 10.1056/NEJMoa1603827
Human studies that measured Liraglutide or used it as a comparator
Indexed as human studies in PubMed, but participants were not given Liraglutide as the studied intervention, or the record does not establish that they were. They describe measurements or comparisons, not the effect of administering the compound.
- Human study · PubMed trial index Comparator arm for another drug
Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
Rubino DM, Greenway FL, Khalid U et al. · JAMA · 2022
PMID 35015037 · DOI: 10.1001/jama.2021.23619 · Registration NCT04074161
Preclinical research, reviews & other publications
Animal studies, laboratory experiments, reviews and other indexed papers answer different questions. A review is secondary evidence; a case report does not estimate how often an outcome occurs.
- Preclinical / laboratory research
The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.
Secher A, Jelsing J, Baquero AF et al. · The Journal of clinical investigation · 2014
PMID 25202980 · DOI: 10.1172/JCI75276
- Preclinical / laboratory research
Liraglutide attenuates type 2 diabetes mellitus-associated non-alcoholic fatty liver disease by activating AMPK/ACC signaling and inhibiting ferroptosis.
Guo T, Yan W, Cui X et al. · Molecular medicine (Cambridge, Mass.) · 2023
PMID 37770820 · DOI: 10.1186/s10020-023-00721-7
Liraglutide supplier sources
Scientific sources describe molecules and experiments. The commercial links below identify recorded supplier packages. A publication or chemical database entry does not verify the seller, purity, sterility or contents of a lot. Some links are affiliate links; see our disclosure.
Liraglutide for sale: compare prices, sizes and forms from every tracked supplier →
| Supplier | Recorded packages | Example source listing |
|---|---|---|
| Amino USAUSD | 5mg Vial1 recorded offers | 5mg Vial · $51.00Checked Nov 6, 2026Supplier listing, Liraglutide 5mg Vial, Amino USA, opens in a new tab |
Reference sources & further reading
- PubChem compound record 16134956 — chemical identity and structure.
- ChEMBL drug record CHEMBL4084119 — development stage, mechanism and synonyms.
- FDA Global Substance Registration System: UNII 839I73S42A — substance identity, names and codes.
- Drugs@FDA: NDA 022341 — US approval record for a medicine with the same active ingredient.
- Drugs@FDA: NDA 206321 — US approval record for a medicine with the same active ingredient.
- Wikipedia: Liraglutide — Background encyclopedia; not a primary clinical source.
The citations above link directly to publication records. Encyclopedia links are background reading and are not used to establish clinical effectiveness.
Search for additional research
These links run searches; their results have not been individually reviewed and can include unrelated compounds.
Research information is not a dosing guide or a recommendation for personal use. Study findings are specific to the formulation, population and methods tested. Read our source and correction policy.
Related research profiles
Cagrilintide
C194H312N54O59S2
4409 g/mol · PubChem CID 171397054
5 selected publications · 4 human intervention studies · 40 registered trials
Protein / peptide · highest stage: Phase 3
Eloralintide
Molecular identity needs further verification
4 selected publications · 3 human intervention studies · 22 registered trials
Mazdutide
C207H317N45O65
4476 g/mol · PubChem CID 167312357
7 selected publications · 6 human intervention studies · 40 registered trials
Protein / peptide · highest stage: Phase 3
Orforglipron Capsules
C48H48F2N10O5
883.0 g/mol · PubChem CID 137319706
8 selected publications · 6 human intervention studies · 40 registered trials
Small molecule · highest stage: Phase 3
Retatrutide
C221H342N46O68
4731 g/mol · PubChem CID 171390338
9 selected publications · 7 human intervention studies · 34 registered trials
Semaglutide
C187H291N45O59
4114 g/mol · PubChem CID 56843331
8 selected publications · 5 human intervention studies · 34 registered trials
US: active ingredient of an FDA-approved medicine · Drugs@FDA
Protein / peptide · highest stage: Approved in at least one jurisdiction (ChEMBL phase 4)